Clinical Trial Results:
A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, noninfectious, intermediate, posterior, or panuveitis requiring immunosuppression (INSURE Study)
Summary
|
|
EudraCT number |
2009-015509-38 |
Trial protocol |
DE GB HU GR ES |
Global completion date |
10 Feb 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Oct 2016
|
First version publication date |
13 Oct 2016
|
Other versions |
|
Summary report(s) |
CAIN457C2302E1_NovCTR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.